Morgan Stanley’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-134,674
| Closed | -$23.2M | – | 8392 |
|
|
2021
Q3 | $23.2M | Buy |
134,674
+49,484
| +58% | +$6.47M | ﹤0.01% | 1938 |
|
|
2021
Q2 | $10.7M | Buy |
85,190
+60,797
| +249% | +$7.67M | ﹤0.01% | 2898 |
|
|
2021
Q1 | $3.31M | Buy |
24,393
+296
| +1% | +$38.2K | ﹤0.01% | 3835 |
|
|
2020
Q4 | $3.08M | Buy |
24,097
+5,492
| +30% | +$644K | ﹤0.01% | 3780 |
|
|
2020
Q3 | $2.09M | Sell |
18,605
-4,681
| -20% | -$466K | ﹤0.01% | 3619 |
|
|
2020
Q2 | $2.22M | Sell |
23,286
-3,839
| -14% | -$370K | ﹤0.01% | 3504 |
|
|
2020
Q1 | $2.44M | Sell |
27,125
-54,346
| -67% | -$4.22M | ﹤0.01% | 3185 |
|
|
2019
Q4 | $4.32M | Buy |
81,471
+42,349
| +108% | +$1.93M | ﹤0.01% | 3351 |
|
|
2019
Q3 | $1.55M | Buy |
39,122
+17,438
| +80% | +$757K | ﹤0.01% | 4012 |
|
|
2019
Q2 | $890K | Sell |
21,684
-9,768
| -31% | -$404K | ﹤0.01% | 4281 |
|
|
2019
Q1 | $1.47M | Sell |
31,452
-49,569
| -61% | -$2.18M | ﹤0.01% | 3842 |
|
|
2018
Q4 | $3.53M | Sell |
81,021
-32,381
| -29% | -$1.62M | ﹤0.01% | 3279 |
|
|
2018
Q3 | $6.49M | Sell |
113,402
-169,208
| -60% | -$8.32M | ﹤0.01% | 2903 |
|
|
2018
Q2 | $13.7M | Buy |
282,610
+160,386
| +131% | +$5.84M | ﹤0.01% | 2028 |
|
|
2018
Q1 | $4.78M | Buy |
122,224
+15,454
| +14% | +$657K | ﹤0.01% | 3070 |
|
|
2017
Q4 | $4.53M | Buy |
106,770
+28,594
| +37% | +$1.07M | ﹤0.01% | 3215 |
|
|
2017
Q3 | $2.92M | Buy |
78,176
+12,649
| +19% | +$439K | ﹤0.01% | 3514 |
|
|
2017
Q2 | $1.99M | Sell |
65,527
-2,135
| -3% | -$61.9K | ﹤0.01% | 3798 |
|
|
2017
Q1 | $1.79M | Sell |
67,662
-77,491
| -53% | -$2.04M | ﹤0.01% | 3904 |
|
|
2016
Q4 | $3.7M | Sell |
145,153
-666,596
| -82% | -$21.1M | ﹤0.01% | 3311 |
|
|
2016
Q3 | $29.4M | Buy |
811,749
+762,262
| +1,540% | +$25.3M | 0.01% | 1176 |
|
|
2016
Q2 | $1.68M | Sell |
49,487
-36,620
| -43% | -$1.19M | ﹤0.01% | 3564 |
|
|
2016
Q1 | $2.27M | Buy |
86,107
+72,915
| +553% | +$2.12M | ﹤0.01% | 3244 |
|
|
2015
Q4 | $644K | Sell |
13,192
-2,845
| -18% | -$102K | ﹤0.01% | 4353 |
|
|
2015
Q3 | $399K | Sell |
16,037
-3,583
| -18% | -$108K | ﹤0.01% | 4739 |
|
|
2015
Q2 | $621K | Sell |
19,620
-417
| -2% | -$13.5K | ﹤0.01% | 4552 |
|
|
2015
Q1 | $763K | Sell |
20,037
-988
| -5% | -$39.3K | ﹤0.01% | 4334 |
|
|
2014
Q4 | $819K | Sell |
21,025
-120
| -0.6% | -$4.18K | ﹤0.01% | 4311 |
|
|
2014
Q3 | $640K | Sell |
21,145
-1,678
| -7% | -$47.3K | ﹤0.01% | 4396 |
|
|
2014
Q2 | $775K | Sell |
22,823
-162
| -0.7% | -$5.42K | ﹤0.01% | 4257 |
|
|
2014
Q1 | $793K | Sell |
22,985
-16,651
| -42% | -$751K | ﹤0.01% | 4192 |
|
|
2013
Q4 | $1.57M | Buy |
+39,636
| New | +$957K | ﹤0.01% | 3564 |
|
Morgan Stanley's XLRN Position: Q4 2021 in Review
Morgan Stanley sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 134,674 shares — an estimated $23.2M sold.
Morgan Stanley first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $29.4M in Q3 2016. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Morgan Stanley reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Morgan Stanley sold 134,674 Acceleron Pharma shares in Q4 2021, an estimated $23.2M.
- Morgan Stanley first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Morgan Stanley's Acceleron Pharma position peaked at $29.4M in Q3 2016.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.